Tumefactive Multiple Sclerosis: Emerging Role of MR Spectroscopy

2018 ◽  
Vol 26 ◽  
pp. 248
Author(s):  
S.A. Siddiqi ◽  
M.C. Pires ◽  
J. Inshasi
2016 ◽  
Vol 8 (2) ◽  
pp. 179-184 ◽  
Author(s):  
Kristen Lew ◽  
Nishith Mewada ◽  
Sahana Ramanujam ◽  
Bahareh Hassanzadeh ◽  
John E. Donahue ◽  
...  

We report a 35-year-old healthy male who developed central nervous system inflammatory demyelinating disease consistent with tumefactive multiple sclerosis. About 2 weeks after onset of symptoms and prior to initiation of therapy, the patient had lymphopenia and low CD4 and CD8 levels. His lymphocyte count was 400 cells/µl (850–3,900 cells/µl), CD4 was 193 cells/µl (490–1,740 cells/µl) and CD8 was 103 cells/µl (180–1,170 cells/µl). He was treated with intravenous methylprednisolone followed by therapeutic plasma exchange, the levels of CD4 and CD8 normalized, and ultimately, he recovered completely.


Sign in / Sign up

Export Citation Format

Share Document